DYNE THERAPEUTICS INC (DYN) Stock Analyst Earnings Estimates
NASDAQ:DYN - Nasdaq - US26818M1080 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 11,735.05% | N/A 233.79% | N/A 115.90% | N/A 64.23% | N/A 38.95% | N/A 21.24% | ||||||||
| EBITDA YoY % growth | -4.78M | -13.56M -183.68% | -57.95M -327.36% | -148.94M -157.01% | -169.28M -13.66% | -240.489M -42.07% | -342.213M -42.30% | N/A -30.22% | N/A -10.12% | N/A 13.10% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.8M | -13.83M -188.13% | -58.65M -324.08% | -150.03M -155.81% | -170.96M -13.95% | -242.162M -41.65% | -343.886M -42.01% | N/A -38.83% | N/A -7.40% | N/A 7.67% | N/A 24.06% | N/A 70.72% | N/A 326.74% | N/A 144.39% | N/A 44.36% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.91 -15.59% | -3.24 -11.34% | -3.94 -21.60% | -3.35 14.97% | N/A -20.30% | N/A 1.65% | N/A 14.73% | N/A 35.02% | N/A 77.46% | N/A 394.55% | N/A 123.45% | N/A 43.05% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.90 6.44% | -0.90 -2.22% | -0.94 10.38% | -0.93 4.21% | -0.93 -3.45% | -0.91 -1.05% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | -115.14M -10.25% | -113.12M -18.53% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -121.097M -14.61% | -124.826M -28.54% | -127.536M -4.22% | -108.868M 5.98% | -109.106M 9.90% | -109.348M 12.40% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.97 -38.57% | -0.96 | -0.01 | -0.60% |
| Q1 2025 Q2Q % growth | -1.05 -29.63% | -0.89 | -0.16 | -18.24% |
| Q4 2024 Q2Q % growth | -0.88 19.27% | -0.97 | 0.09 | 9.33% |
| Q3 2024 Q2Q % growth | -0.96 3.03% | -0.72 | -0.24 | -33.50% |
| Q2 2024 Q2Q % growth | -0.70 35.19% | -0.73 | 0.03 | 3.47% |
| Q1 2024 Q2Q % growth | -0.81 -3.85% | -0.81 | 0.00 | -0.25% |
| Q4 2023 Q2Q % growth | -1.09 -47.30% | -0.93 | -0.16 | -17.73% |
| Q3 2023 Q2Q % growth | -0.99 -23.75% | -0.84 | -0.15 | -17.74% |
| Q2 2023 Q2Q % growth | -1.08 -6.93% | -0.82 | -0.26 | -32.42% |
| Q1 2023 Q2Q % growth | -0.78 -13.04% | -0.78 | 0.00 | -0.46% |
| Q4 2022 Q2Q % growth | -0.74 26.00% | -0.85 | 0.11 | 13.29% |
| Q3 2022 Q2Q % growth | -0.80 3.61% | -0.93 | 0.13 | 14.06% |
| Q2 2022 Q2Q % growth | -1.01 -74.14% | -0.78 | -0.23 | -29.03% |
| Q1 2022 Q2Q % growth | -0.69 -38.00% | -0.89 | 0.20 | 22.59% |
| Q4 2021 Q2Q % growth | -1.00 -56.25% | -1.00 | 0.00 | -0.01% |
| Q3 2021 Q2Q % growth | -0.83 58.71% | -0.65 | -0.18 | -27.41% |
| Q2 2021 Q2Q % growth | -0.58 | -0.55 | -0.03 | -5.37% |
| Q1 2021 Q2Q % growth | -0.50 | -0.61 | 0.11 | 17.77% |
| Q4 2020 Q2Q % growth | -0.64 | -0.38 | -0.26 | -70.34% |
| Q3 2020 Q2Q % growth | -2.01 | -0.88 | -1.13 | -127.44% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 8.32% | 8.85% | 0% | -10.71% |
| Revenue | N/A | N/A | N/A | N/A |